Better Therapeutics price target lowered to $3 from $5 at Lake Street

Lake Street analyst Thomas Flaten lowered the firm’s price target on Better Therapeutics to $3 from $5 and keeps a Buy rating on the shares after Better reported Q2 results. The firm sees the reality of Better’s markets “coming into sharper focus” as the company “moves steadily closer to commercialization of AspyreRx,” but lowered its price target to reflect updated revenue estimates and dilution from the recent financing, the analyst tells investors.